The relationship between IL-10 levels and cardiovascular events in patients with CKD

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 7, 2014, Pages 1207-1216

  Yilmaz, Mahmut Ilker ^a   Solak, Yalcin ^b   Saglam, Mutlu ^a   Cayci, Tuncer ^a   Acikel, Cengizhan ^a   Unal, Hilmi Umut ^a   Eyileten, Tayfun ^a   Oguz, Yusuf ^a   Sari, Sebahattin ^a   Carrero, Juan Jesus ^c   Stenvinkel, Peter ^c   Covic, Adrian ^d   Kanbay, Mehmet ^e  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Karaman State Hospital   (Turkey)

^c KAROLINSKA INSTITUTE   (Sweden)

^d C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^e ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PENTRAXIN 3; PHOSPHORUS; AUTACOID; BIOLOGICAL MARKER; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; SERUM AMYLOID P;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DILATATION; DISEASE ASSOCIATION; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; SURVIVAL RATE; VASODILATATION; AGED; BLOOD; BLOOD FLOW; CARDIOVASCULAR DISEASES; COMPLICATION; CROSS-SECTIONAL STUDY; KAPLAN MEIER METHOD; KIDNEY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; TIME; UPREGULATION; VASCULAR ENDOTHELIUM;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SERUM AMYLOID P-COMPONENT; TIME FACTORS; UP-REGULATION; VASODILATION;

EID: 84923788718     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08660813     Document Type: Article

References (26)

1. McCullough PA, Steigerwalt S, Tolia K, Chen SC, Li S, Norris KC, Whaley-Connell A; KEEP Investigators: Cardiovascular disease in chronic kidney disease: Data from the Kidney Early Evaluation Program (KEEP). Curr Diab Rep 11: 47-55, 2011
2. Massy ZA, Stenvinkel P, Drueke TB: The role of oxidative stress in chronic kidney disease. Semin Dial 22: 405-408, 2009
3. de Vries JE: Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 27: 537-541, 1995
4. Morita Y, Yamamura M, Kashihara N, Makino H: Increased production of interleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients. Res Commun Mol Pathol Pharmacol 98: 19-33, 1997
5. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, GirndtM: IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int 67: 1216-1233, 2005
6. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM; CAPTURE Study Investigators: Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107: 2109-2114, 2003
7. Mälarstig A, Eriksson P, Hamsten A, Lindahl B, Wallentin L, Siegbahn A: Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart 94: 724-729, 2008
8. Girndt M, Kaul H, Sester U, Ulrich C, Sester M, Georg T, Köhler H: Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 62: 949-955, 2002
9. Straczkowski M, Kowalska I, Nikolajuk A, Krukowska A, Gorska M: Plasma interleukin-10 concentration is positively related to insulin sensitivity in young healthy individuals. Diabetes Care 28: 2036-2037, 2005
10. Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 109[Suppl 1]: III27-III32, 2004
11. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972
12. National Kidney Foundation: K/DOQI clinical practice guidelines for bonemetabolismand disease in chronic kidney disease. Am J Kidney Dis 42[4 Suppl 3]: S1-S201, 2003
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
14. Song S, Ling-Hu H, Roebuck KA, Rabbi MF, Donnelly RP, Finnegan A: Interleukin-10 inhibits interferon-gamma-induced intercellular adhesion molecule-1 gene transcription in human monocytes. Blood 89: 4461-4469, 1997
15. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340: 1111-1115, 1992
16. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard- Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force: Guidelines for the ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39: 257-265, 2002
17. Von Der Thüsen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ, Biessen EA: Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J 15: 2730-2732, 2001
18. Mallat Z, Heymes C, Ohan J, Faggin E, Lesèche G, Tedgui A: Expression of interleukin-10 in advanced human atherosclerotic plaques: Relation to inducible nitric oxide synthase expression and cell death. Arterioscler ThrombVasc Biol 19: 611-616, 1999
19. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM: IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96: 2304-2310, 1995
20. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA, Fyfe AI: Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 19: 2847-2853, 1999
21. Cavusoglu E, Marmur JD, Hojjati MR, Chopra V, Butala M, Subnani R, Huda MS, Yanamadala S, Ruwende C, Eng C, Pinsky DJ: Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med 124: 724-730, 2011
22. Eskdale J, Gallagher G: A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics 42: 444-445, 1995
23. Koch W, Kastrati A, Böttiger C, Mehilli J, von Beckerath N, Schömig A: Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 159: 137-144, 2001
24. Weber C, Sigrist M, Romann A, Chiarelli G, Levin A: Novel biomarkers do not correlate with severity of vascular stiffness in CKD patients with severe co-morbid disease. Nephron Clin Pract 119: c261-c268, 2011
25. Brunet P, Capo C, Dellacasagrande J, Thirion X, Mege JL, Berland Y: IL-10 synthesis and secretion by peripheral blood mononuclear cells in haemodialysis patients. Nephrol Dial Transplant 13: 1745-1751, 1998
26. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A: Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 27: 1262-1264, 1999